^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CYP17A1 inhibitor

2d
Restoration of melatonin rhythms reduces tumour-promoting inflammation in oesophageal cancer survivors: a prospective cohort study. (PubMed, Front Immunol)
Blunted nocturnal melatonin amplitude is linked to tumour-promoting inflammation in oesophageal-cancer survivors, but it is unclear whether restoring endogenous rhythms improves clinical outcomes...Behavioural realignment of endogenous melatonin rhythms was associated with sustained reductions in systemic inflammation and fewer adverse events in oesophageal-cancer survivors. Routine circadian-hygiene counselling combined with simple salivary monitoring may help support long-term oncologic and cardiometabolic health.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
Akeega (abiraterone/niraparib)
4d
Clocking immunity: circadian modulation of NK cells and emerging timing perspectives. (PubMed, Front Immunol)
Current data support a circadian influence on NK biology, but the direction and magnitude of reported effects vary across species, sampling schedules, circadian phase definitions, tissue compartments, and NK-cell readouts. This heterogeneity underscores the need for longitudinal, high-frequency sampling with complementary continuous monitoring to define phase, amplitude, and stability across physiological and clinical contexts.
Review • Journal
|
IFNG (Interferon, gamma) • PER1 (Period Circadian Clock 1)
|
Akeega (abiraterone/niraparib)
4d
NMDA receptor mediated tonic excitatory currents are elicited by EAAT inhibition on human neocortical pyramidal neurons. (PubMed, Front Synaptic Neurosci)
The tonic current was only partially reverted by the GluN2B subunit specific NMDA receptor (NMDAR) antagonist ifenprodil, whereas SICs were almost fully eliminated. The amplitude of the current was inversely proportional with the age of the patient and disappeared in elderly over the age of 70...In summary, NMDAR-dependent tonic inward currents are overlapping but partially separable phenomena from SICs. One might hypothesize that the tonic current is only present under excitotoxic conditions and do not determine physiological neuronal excitability in human.
Journal
|
GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B)
|
Akeega (abiraterone/niraparib)
5d
Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models. (PubMed, Mol Imaging Biol)
Direct AR antagonism enhances functional PSMA availability and increases short-term uptake of PSMA-targeted radioligands in AR-positive prostate cancer models. These findings provide mechanistic support for AR-mediated modulation of PSMA-targeted radioligand delivery and warrant further translational investigation.
Preclinical • Journal
|
AR (Androgen receptor) • FOLH1 (Folate hydrolase 1)
|
AR positive • FOLH1 expression
|
enzalutamide • abiraterone acetate • apalutamide
10d
New P2 trial
|
abiraterone acetate • Eligard (leuprolide acetate) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)
10d
A mouse model of mechanical stress injury to the basal ganglia using thermosensitive PNIPAM hydrogel for intracerebral hemorrhage research. (PubMed, Animal Model Exp Med)
This newly established model of mechanical stress injury effectively recapitulates the pathophysiology of CST damage following ICH. It also provides a simple and reproducible tool for conducting preclinical studies on mechanical stress-induced WMI in ICH.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Akeega (abiraterone/niraparib)
12d
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. (clinicaltrials.gov)
P2, N=192, Recruiting, Sun Pharmaceutical Industries Limited | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Dec 2027
Enrollment open • Trial completion date • Trial primary completion date
|
enzalutamide • apalutamide • Yonsa (abiraterone acetate)
14d
Whole-body tomographic fluorescence lifetime imaging of PD-L1 expression. (PubMed, Res Sq)
Multi-exponential analysis of time-domain fluorescence data was used to derive four amplitude-based metrics of PD-L1 expression...Among the evaluated metrics, a normalized parameter that accounts for inter-lifetime crosstalk demonstrated the strongest correlation with ex vivo PD-L1 expression (r 2  = 0.77). These findings establish a foundation for a noninvasive, nonionizing imaging approach to quantify and monitor receptor expression and support a future path for the longitudinal assessment of immune biomarkers in both preclinical studies and clinical settings.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Akeega (abiraterone/niraparib)
15d
A wearable biosensing platform for continuous monitoring of inflammatory and metabolic biomarkers for real-time health tracking and personalized care. (PubMed, Bioeng Transl Med)
Older participants showed dampened amplitudes, phase shifts, and inflammatory dominance...These findings establish sweat as a valid, real-time medium for capturing endocrine and immune cycles, with analytical tools capable of uncovering early physiological strain. This work lays a foundation for personalized chronobiological monitoring and stress-risk screening in naturalistic settings.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
Akeega (abiraterone/niraparib)
15d
Effects of Vagal Nerve Stimulation on Rectal Tone and Distal Colon Transit in Rats Mediated via the Vagal-Sacral Pathway. (PubMed, Cells)
VNS was applied with varying frequencies, pulse widths, and amplitudes...VNS modulates distal colon transit and rectal tone through coordinated nitrergic and cholinergic signaling and central vagal-to-sacral circuits. These findings reveal functional crosstalk between vagal and sacral parasympathetic pathways and provide mechanistic insight into potential VNS therapy for lower GI disorders.
Preclinical • Journal
|
FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
|
Akeega (abiraterone/niraparib)
15d
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results. (PubMed, Eur J Nucl Med Mol Imaging)
In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.
Journal
|
FOLH1 (Folate hydrolase 1) • ARSI (Arylsulfatase Family Member I)
|
FOLH1 expression
|
enzalutamide • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)